$CTIX News
Cellceutix Brilacidin IND effective, Phase 2 to begin 10:31 a.m. Oct. 13, 2014 - Seeking Alpha
Regulatory Support Creates Opportunity For Antibiotic Makers Otonomy And Cellceutix 10:02 a.m. Sept. 25, 2014 - Seeking Alpha
Update: Cellceutix Calls Out To President Obama About Brilacidin 3:38 p.m. Sept. 21, 2014 - Seeking Alpha
10-K: CELLCEUTIX CORP 1:53 p.m. Sept. 15, 2014 - Edgar Online - (EDG = 10Q, 10K)
Update: Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol 3:06 a.m. Sept. 14, 2014 - Seeking Alpha
The Antibiotic Resistance Triple Threat 2:05 p.m. Sept. 4, 2014 - Seeking Alpha
Cellceutix completes enrollment in Brilacidin trial 9:45 a.m. Aug. 19, 2014 - Seeking Alpha
Did The Medicines Company Trump Cellceutix And Others In A $1B-Plus Skin Infection Market? 11:38 a.m. Aug. 14, 2014 - Seeking Alpha
10-Q: CELLCEUTIX CORP 10:15 a.m. May 12, 2014 - Edgar Online - (EDG = 10Q, 10K)
Huge Opportunities Are Now Possible Due To Market Inefficiencies In Valuing Antibiotic Companies Such As Cubist, Durata, And Cellceutix 10:34 a.m. April 25, 2014 - Seeking Alpha
10-Q: CELLCEUTIX CORP 5:09 p.m. Feb. 10, 2014 - Edgar Online - (EDG = 10Q, 10K)
Cellceutix Is Significantly Undervalued Considering The Value Of Brilacidin 10:31 a.m. Jan. 28, 2014 - Seeking Alpha
Cellceutix Corp.: A Biotech With High Risk But High Reward 4:17 p.m. Jan. 2, 2014 - Wall St. Cheat Sheet
Cellceutix: An Undiscovered Company Set To Rise In 2014 10:06 a.m. Dec. 16, 2013 - Seeking Alpha
3 Innovative Biotech Companies Poised To Shine At TAP Partnership Conference 6:38 a.m. Nov. 19, 2013 - Seeking Alpha
10-Q: CELLCEUTIX CORP 6:06 p.m. Nov. 8, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-K: CELLCEUTIX CORP 4:01 p.m. Sept. 30, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: CELLCEUTIX CORP 2:18 p.m. May 20, 2013 - Edgar Online - (EDG = 10Q, 10K)
Interview with CEO of Cellceutix Corporation: Leo Ehrlich 9:57 a.m. Nov. 15, 2011 - GuruFocus.com
Cellceutix's New Chief Operating Officer Dr. James Alexander Addresses Shareholders 7:00 a.m. Oct. 31, 2014 - Marketwired
Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin 11:52 a.m. Oct. 23, 2014 - Marketwired
Cellceutix Investigational New Drug (IND) Application Becomes Effective, Selects First Site for Phase 2 Clinical Trial of New Treatment for Oral Mucositis 9:02 a.m. Oct. 13, 2014 - Marketwired
Cellceutix Provides Update to Shareholders 12:30 p.m. Sept. 24, 2014 - Marketwire
Cellceutix to President Obama: We Have the Tools and Will Rise Up to the Challenge to Prevent Antibiotic Resistant Bacteria Becoming a Serious Threat to Public Health 7:15 a.m. Sept. 19, 2014 - Marketwire
Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis 3:01 p.m. Sept. 9, 2014 - Marketwire
Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference 11:17 a.m. Sept. 5, 2014 - Marketwire
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting 7:01 a.m. Sept. 2, 2014 - Marketwire
Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 8:31 a.m. Aug. 19, 2014 - Marketwire
Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis 7:01 a.m. Aug. 11, 2014 - Marketwire
Cellceutix Anti-Psoriasis Drug Prurisol Meets Primary Endpoint of Clinical Trial 6:04 a.m. Aug. 8, 2014 - Marketwire
Cellceutix Believes Brilacidin on Track to Help U.S. Avoid Falling Into Post-Antibiotic Era; Completion of Enrollment in Phase 2b Trial for Acute Bacterial Skin and Skin Structure Infections Expected This Month 7:01 a.m. Aug. 4, 2014 - Marketwire
Cellceutix Announces Breakthrough in the Formulation of Its Novel Antibiotic Brilacidin(TM), Plans Studies to Treat Diabetic Foot Ulcers 7:01 a.m. July 14, 2014 - Marketwire
Cellceutix Brilacidin ABSSSI Trial Gets Positive Review by Data Safety Monitoring Board; Best Possible Outcome, No Treatment-Related Serious Adverse Events (SAEs) 7:00 a.m. July 7, 2014 - Marketwire
Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant 7:01 a.m. June 23, 2014 - Marketwire
Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering Eighth Cohort 7:01 a.m. June 16, 2014 - Marketwire
Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol 7:02 a.m. June 2, 2014 - Marketwire
Cellceutix Signs Material Transfer Agreements for Defensin Mimetic Compounds With Leading Universities 7:02 a.m. May 27, 2014 - Marketwire
Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market 7:01 a.m. May 19, 2014 - Marketwire
Cellceutix Confident in Its Formidable Antibiotic Arsenal 7:01 a.m. May 12, 2014 - Marketwire
Cellceutix Brilacidin IND effective, Phase 2 to begin 10:31 a.m. Oct. 13, 2014 - Seeking Alpha
Regulatory Support Creates Opportunity For Antibiotic Makers Otonomy And Cellceutix 10:02 a.m. Sept. 25, 2014 - Seeking Alpha
Update: Cellceutix Calls Out To President Obama About Brilacidin 3:38 p.m. Sept. 21, 2014 - Seeking Alpha
10-K: CELLCEUTIX CORP 1:53 p.m. Sept. 15, 2014 - Edgar Online - (EDG = 10Q, 10K)
Update: Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol 3:06 a.m. Sept. 14, 2014 - Seeking Alpha
The Antibiotic Resistance Triple Threat 2:05 p.m. Sept. 4, 2014 - Seeking Alpha
Cellceutix completes enrollment in Brilacidin trial 9:45 a.m. Aug. 19, 2014 - Seeking Alpha
Did The Medicines Company Trump Cellceutix And Others In A $1B-Plus Skin Infection Market? 11:38 a.m. Aug. 14, 2014 - Seeking Alpha
10-Q: CELLCEUTIX CORP 10:15 a.m. May 12, 2014 - Edgar Online - (EDG = 10Q, 10K)
Huge Opportunities Are Now Possible Due To Market Inefficiencies In Valuing Antibiotic Companies Such As Cubist, Durata, And Cellceutix 10:34 a.m. April 25, 2014 - Seeking Alpha
10-Q: CELLCEUTIX CORP 5:09 p.m. Feb. 10, 2014 - Edgar Online - (EDG = 10Q, 10K)
Cellceutix Is Significantly Undervalued Considering The Value Of Brilacidin 10:31 a.m. Jan. 28, 2014 - Seeking Alpha
Cellceutix Corp.: A Biotech With High Risk But High Reward 4:17 p.m. Jan. 2, 2014 - Wall St. Cheat Sheet
Cellceutix: An Undiscovered Company Set To Rise In 2014 10:06 a.m. Dec. 16, 2013 - Seeking Alpha
3 Innovative Biotech Companies Poised To Shine At TAP Partnership Conference 6:38 a.m. Nov. 19, 2013 - Seeking Alpha
10-Q: CELLCEUTIX CORP 6:06 p.m. Nov. 8, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-K: CELLCEUTIX CORP 4:01 p.m. Sept. 30, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: CELLCEUTIX CORP 2:18 p.m. May 20, 2013 - Edgar Online - (EDG = 10Q, 10K)
Interview with CEO of Cellceutix Corporation: Leo Ehrlich 9:57 a.m. Nov. 15, 2011 - GuruFocus.com
Cellceutix's New Chief Operating Officer Dr. James Alexander Addresses Shareholders 7:00 a.m. Oct. 31, 2014 - Marketwired
Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin 11:52 a.m. Oct. 23, 2014 - Marketwired
Cellceutix Investigational New Drug (IND) Application Becomes Effective, Selects First Site for Phase 2 Clinical Trial of New Treatment for Oral Mucositis 9:02 a.m. Oct. 13, 2014 - Marketwired
Cellceutix Provides Update to Shareholders 12:30 p.m. Sept. 24, 2014 - Marketwire
Cellceutix to President Obama: We Have the Tools and Will Rise Up to the Challenge to Prevent Antibiotic Resistant Bacteria Becoming a Serious Threat to Public Health 7:15 a.m. Sept. 19, 2014 - Marketwire
Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis 3:01 p.m. Sept. 9, 2014 - Marketwire
Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference 11:17 a.m. Sept. 5, 2014 - Marketwire
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting 7:01 a.m. Sept. 2, 2014 - Marketwire
Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 8:31 a.m. Aug. 19, 2014 - Marketwire
Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis 7:01 a.m. Aug. 11, 2014 - Marketwire
Cellceutix Anti-Psoriasis Drug Prurisol Meets Primary Endpoint of Clinical Trial 6:04 a.m. Aug. 8, 2014 - Marketwire
Cellceutix Believes Brilacidin on Track to Help U.S. Avoid Falling Into Post-Antibiotic Era; Completion of Enrollment in Phase 2b Trial for Acute Bacterial Skin and Skin Structure Infections Expected This Month 7:01 a.m. Aug. 4, 2014 - Marketwire
Cellceutix Announces Breakthrough in the Formulation of Its Novel Antibiotic Brilacidin(TM), Plans Studies to Treat Diabetic Foot Ulcers 7:01 a.m. July 14, 2014 - Marketwire
Cellceutix Brilacidin ABSSSI Trial Gets Positive Review by Data Safety Monitoring Board; Best Possible Outcome, No Treatment-Related Serious Adverse Events (SAEs) 7:00 a.m. July 7, 2014 - Marketwire
Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant 7:01 a.m. June 23, 2014 - Marketwire
Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering Eighth Cohort 7:01 a.m. June 16, 2014 - Marketwire
Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol 7:02 a.m. June 2, 2014 - Marketwire
Cellceutix Signs Material Transfer Agreements for Defensin Mimetic Compounds With Leading Universities 7:02 a.m. May 27, 2014 - Marketwire
Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market 7:01 a.m. May 19, 2014 - Marketwire
Cellceutix Confident in Its Formidable Antibiotic Arsenal 7:01 a.m. May 12, 2014 - Marketwire
